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PHARMACY NEWS
Take Home dispensing time reduced
To achieve timely dispensing of Take Home,
Pharmacy department initiated a project in which
Take Home orders of specific pharmacies (C1,
C2) have been diverted to a single pharmacy
(Peads) for a specific duration of time (from
12:00-4:00 pm). The concept of Take Home phar-
macy has resulted in speedy delivery of Take
Home medications. The mean take home dis-
pensing time was reduced from 50 minutes to 30
minutes.
High alert medications
This policy intends to provide specific written pro-
cedures for the safe storage, prescribing,  dis-
pensing, administration and handling of
concentrated electrolytes  that have been desig-
nated as high-alert medications by JCIA . Cur-
rently a project has been initiated that involves
dispensing of premixed/diluted High Alert Medica-
tions including Potassium Chloride, Potassium
Phosphate, Magnesium Sulfate and Hypertonic
Saline, and 100% beds have been covered
through this.
Poster presentation
Pharmacist Shaukat Ali Muttaqi Shah  presented
a poster (Quantitative Analysis of Drug-Drug In-
teraction in Ambulatory Care Setting) in a con-
gress at Basel, Switzerland. The presentation
was organised by Federation of International
Pharmaceuticals (FIP).
Clinical pharmacy services coverage
The floors covered by clinical pharmacists in-
clude:
ICU, CICU, CCU, NICU, Peads, C2 post call,
stroke unit, Gastroenterology, Psychiatry and On-
cology. Through pharmacists’ intervention, total
cost avoidance in the year 2008 is: 
Rs 9,845,000.
Reducing errors related to Look Alike Sound
Alike drugs (LASA)
A multidisciplinary project was completed with the
target of reducing the errors associated with
LASA drugs to 50%. The major interventions of
the group to achieve the target were: TALL man
lettering, use of cautionary labels for look-alike
drugs and computer alerts for physician and
nurses for LASA drugs.
Height weight update through Computerised
Physician Order Entry (CPOE)
Patient demographics and related information is
of utmost importance while prescribing drugs and
reviewing the orders. Among these, the height
and weight of patient is a vital and important infor-
mation based upon which the drugs could be pre-
scribed and dispensed in right dose and
frequency. For ensuring compliance, Pharmacy in
collaboration with IT worked to ensure the avail-
ability of this information to users prescribing, re-
viewing and dispensing the medications. Since
children are more prone to dose variations and
the right dose and frequency is detrimental in
avoiding treatment failure or overdose, the team
selected this group of patients for the implemen-
tation of this project in initial phase. Therefore
currently no order for a child would be accepted
by the COPE system if the height and weight in-
formation is not updated. A similar process will be
adopted for adult patients in next the phase. 
FDA ALERTS
Alert regarding Clopidogrel
Decrease in effectiveness may be due to genetic
differences or because of interference with other
drugs. FDA recommends the following regarding
clopidogrel use: 
•  Healthcare providers should continue to pre-
scribe and patients should continue to take clopi-
dogrel as directed, because clopidogrel has
demonstrated benefits in preventing blood clots
that could lead to a heart attack or stroke. 
•  Healthcare providers should re-evaluate the
need for starting or continuing treatment with a
PPI in patients taking clopidogrel. 
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Phenytoin
Biphosphonates
OTC cough and cold drugs
Statins
Rituximab
Simvastatin/Ezitimibe
Simvastatin/Amiodarone
Erythropoietin
Bevacizumab
Fluoroquinolone
Antipsychotics
Mycophenolate Mofetil
Montelukast
Heparin Sodium
Varenicline
Antiepileptics
Bisphosphonates
Increased risk of serious skin reactions including Stevens John-
son syndrome (SJS) and toxic epidermal necrolysis (TEN) from
phenytoin therapy in Asian population
No increased risk of atrial fibrillation in patients treated with a
bisphosphonate drug
Modified product labels of OTC cough and cold medicines as
‘do not use’ for children under 2 years of age
New indications amyotrophic lateral sclerosis (ALS), a neurode-
generative disease often referred to as ‘ Lou Gehrig's Disease’
Risk of Progressive multifocal leukoencephalopathy PML
Combination used resulted in large number of cancers and can-
cer associated deaths, whereas no additional CVS protection
observed
Dose dependent adverse effects including Rhabdomyolysis,
muscle injury, renal failure and deaths have been reported with
this combination
Use of Erythropoietin can increase the risks of thrombovascular
events, shortened time to tumor progression or recurrence, and
shortened survival time
Several cases of microangiopathic hemolytic anemia (MAHA) in
patients with solid tumors receiving Avastin in combination with
sunitinib malate
Increased risk of developing tendinitis and tendon rupture in pa-
tients taking fluoroquinolones for systemic use
‘Conventional and atypical antipsychotics’ increases risk of mor-
tality in elderly patients treated for dementia-related psychosis
Reports of infants born with serious congenital anomalies, in-
cluding microtia and cleft lip and palate, following exposure to
mycophenolate mofetil (MMF) during pregnancy
Possible association between the use of  and behavior/mood
changes, suicidality (suicidal thinking and behavior) and suicide
Reports of serious adverse events including allergic or hyper-
sensitivity-type reactions, with symptoms of oral swelling, nau-
sea, vomiting, sweating, shortness of breath, and cases of
severe hypotension
Serious neuropsychiatric symptoms, including changes in be-
havior, agitation, depressed mood, suicidal ideation, and at-
tempted and completed suicide
Patients receiving antiepileptic drugs had approximately twice
the risk of suicidal behavior or ideation (0.43%) compared to pa-
tients receiving placebo (0.22%)
Possibility of severe and sometimes incapacitating bone, joint,
and/or muscle (musculoskeletal) pain in patients taking bisphos-
phonates
Month Drug(s) Summary
Summary of FDA Alerts 2008
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DRUG SAFETY UPDATE
Amiodarone - Fluconazole
Amiodarone (antiarrhythmic, group III) is a potent
‘membrane active’ cationic amphiphilic compound
which has both polar and nonpolar constituents.
While Fluconazole, a triazole antifungal, acts by
inhibiting the fungal cytochrome P-450 dependent
enzyme, lanosterol-14-alph-demethylase. An Ad-
verse drug reaction occurred due to the simulta-
neous use of Fluconazole and Amiodarone, that
is QT-prolongation. As concurrent use of amio-
darone and fluconazole may result in an in-
creased risk of cardiotoxicity (QT prolongation,
torsades de pointes, cardiac arrest) with severity
is major. Strict cardiac monitoring and caution is
required when used concurrently.
N-Acetylcystein (IV)
To protect kidneys from the toxic effects of dyes
used in different procedures (for example pre and
post catheterisation) Acetylcysteine is one of the
drugs of choice. N-Acetylcysteine (NAC) is given
intravenously pre-op and after that oral doses are
given for 48 hours. An adverse effect of rash fol-
lowed by phlebitis was reported, when patient
was given intravenous Acetylcysteine post-op 
instead of oral. Then by discontinuing IV-NAC
patient recovered from the adverse reaction oc-
curred. Advise: injudicious use of IV NAC may 
result in ADRs and hence the proper protocol for
NAC administration should be followed. The
guidelines and research done on the prophylactic
dose of NAC, usually recommends an oral dose
of 600-1200 mg PO Q12h X 4 doses, 2 doses
pre-contrast and 2 doses post-contrast is optimal;
and another option is  IV Acetylcysteine 600-1200
mg IV x 1 over 15 minutes, then 600-1200 mg PO
q12h x 4 doses post-procedure along with hydra-
tion (IV formulation is available for high risk pa-
tient’s with acute ST-elevation MI undergoing
cardiac catheterisation).
Digoxin Toxicity
Digoxin is a cardiac glycoside used in cardiac ar-
rhythmia. Digoxin exerts a positive ionotropic ef-
fect on both the normal and failing heart, which in-
creases linearly with the dose, and is mediated
through inhibition of transmembranous active
transport of sodium and potassium. Since we do
not have Digoxin Immune Fab available in Pak-
istan the treatment modalities for Digoxin over-
dose include anti-arrythmics, charcoal and
cholestyramine. Cholestyramine was found to
have minimal effect on digoxin absorption and ex-
cretion in man but was reported to decrease the
serum digoxin half-life from 75.5 hours to 19.9
hours in a 94 year old man with chronic digoxin
toxicity and renal insufficiency.
ESTABLISHMENT OF A NEW 
ANTI- H.PYLORI REGIMEN:
SEQUENTIAL THERAPY
According to the American College of Gastroen-
terology (2007), an alternative dosing regimen is
sequential therapy. Eradication rates exceeding
90% may be achieved with sequential therapy
consisting of a proton pump inhibitor (40 mg daily)
plus amoxicillin (1 g twice daily) for the first 5
days, followed by PPI(20 mg), clarithromycin (500
mg) and tinidazole (500 mg) twice daily for the re-
maining 5 days or standard 7 days treatment [PPI
(20 mg), clarithromycin (500 mg) and amoxicillin
(1 g) twice daily]. The sequential therapy is well
tolerated by children, adults and elderly patients
and may be superior to clarithromycin-based
triple therapy in patients with clarithromycin-resis-
tant H. pylori infections.
